AEON

Company Overview — What Does AEON Biopharma, Inc. Do?

AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed a Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of both chronic and episodic migraine. AEON Biopharma, Inc. is based in Irvine, California. AEON Biopharma, Inc. (AEON) is classified as a micro-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Marc Forth. With a market capitalization of $25M, AEON is one of the notable companies in the Healthcare sector.

AEON Biopharma, Inc. (AEON) Stock Rating — Reduce (April 2026)

As of April 2026, AEON Biopharma, Inc. receives a Reduce rating with a composite score of 37.1/100 and 2 out of 5 stars from the Blank Capital Research quantitative model.AEON ranks #3,494 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, AEON Biopharma, Inc. ranks #544 of 838 stocks, placing it in the lower half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

AEON Stock Price and 52-Week Range

AEON Biopharma, Inc. (AEON) currently trades at $0.85. The stock gained $0.02 (2.4%) in the most recent trading session. The 52-week high for AEON is $1.45, which means the stock is currently trading -41.4% from its annual peak. The 52-week low is $0.38, putting the stock 126.7% above its annual trough. Recent trading volume was 25K shares, suggesting relatively thin trading activity.

Is AEON Overvalued or Undervalued? — Valuation Analysis

AEON Biopharma, Inc. (AEON) carries a value factor score of 13/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth.

At current multiples, AEON Biopharma, Inc. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

AEON Biopharma, Inc. Profitability — ROE, Margins, and Quality Score

AEON Biopharma, Inc. (AEON) earns a quality factor score of 49/100, signaling below-average profitability metrics relative to the broader market. Return on assets (ROA) comes in at -148.5% versus the sector average of -33.1%.

Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

AEON Debt, Balance Sheet, and Financial Health

Balance sheet data for AEON is evaluated through our stability factor. The current ratio is 0.49x, which may signal near-term liquidity tightness. Total debt on the balance sheet is $12M. Cash and equivalents stand at $13,000.

AEON has a beta of 0.54, meaning it is less volatile than the S&P 500, making it a relatively defensive holding. The stability factor score for AEON Biopharma, Inc. is 33/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

AEON Biopharma, Inc. Revenue and Earnings History — Quarterly Trend

In TTM 2026, AEON Biopharma, Inc. reported revenue of $0 and earnings per share (EPS) of $-3.95. Net income for the quarter was $-8M. Operating income came in at $-11M.

In FY 2025, AEON Biopharma, Inc. reported revenue of $0 and earnings per share (EPS) of $-3.95. Net income for the quarter was $-39M. Operating income came in at $-13M.

In Q3 2025, AEON Biopharma, Inc. reported revenue of $0 and earnings per share (EPS) of $-0.39. Net income for the quarter was $-5M. Operating income came in at $-2M.

In Q2 2025, AEON Biopharma, Inc. reported revenue of $0 and earnings per share (EPS) of $-0.60. Net income for the quarter was $-7M. Operating income came in at $-4M.

Over the past 8 quarters, AEON Biopharma, Inc. has experienced revenue contraction from $0 to $0. Investors analyzing AEON stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

AEON Dividend Yield and Income Analysis

AEON Biopharma, Inc. (AEON) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

AEON Momentum and Technical Analysis Profile

AEON Biopharma, Inc. (AEON) has a momentum factor score of 53/100, reflecting neutral trend characteristics. The stock is neither significantly outperforming nor underperforming the broader market on a momentum basis. The investment factor score is 25/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 14/100 signals elevated short interest, which can indicate bearish sentiment among institutional investors.

AEON vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, AEON Biopharma, Inc. (AEON) ranks #544 out of 838 stocks based on the Blank Capital composite score. This places AEON in the lower half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing AEON against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full AEON vs S&P 500 (SPY) comparison to assess how AEON Biopharma, Inc. stacks up against the broader market across all factor dimensions.

AEON Next Earnings Date

No upcoming earnings date has been announced for AEON Biopharma, Inc. (AEON) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy AEON? — Investment Thesis Summary

The quantitative profile for AEON Biopharma, Inc. suggests caution. The value score of 13/100 indicates premium valuation. High volatility (stability score 33/100) increases portfolio risk.

In summary, AEON Biopharma, Inc. (AEON) earns a Reduce rating with a composite score of 37.1/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on AEON stock.

Related Resources for AEON Investors

Explore more research and tools: AEON vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare AEON head-to-head with peers: AEON vs AZN, AEON vs SLGL, AEON vs VMD.